Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Receives Patent on Novel Pain Management/GI Combination Product; Company to Present Study Data at ACG Annual Meeting in November 2005

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Aug. 16, 2005--POZEN Inc. (NASDAQ: POZN), today announced that the United States Patent and Trademark Office has issued to POZEN U.S. patent number 6,926,907 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs'. This patent includes claims to pharmaceutical compositions that may contain a non-steroidal anti-inflammatory drug (NSAID) and an acid inhibitor, e.g., a proton pump inhibitor (PPI). POZEN's PN (PPI/NSAID) combination drug candidates are covered under this patent.

In the wake of cardiovascular safety concerns regarding the COX-2 selective NSAIDs, physicians are now recommending use of traditional non-selective NSAIDs with acid-suppressive co-therapy to prevent gastrointestinal complications. POZEN's PN drug candidates are being designed to provide this type of therapy with the added benefit of ensuring adherence with the use of the gastroprotective PPI with every dose of NSAID.

The POZEN PN tablet is designed to initially release the PPI component in the stomach and the NSAID component is released only in a lower acid environment. POZEN completed a 14-day proof-of-concept study with its drug candidate PN 100 which demonstrated that PN 100 was highly effective in preventing gastric mucosal injury compared with an NSAID alone. The results of this study have been selected for platform presentation at the Annual Scientific Meeting of the American College of Gastroenterology in November.

The PN drug candidates are being developed for the management of pain and inflammation associated with conditions such as osteoarthritis, which affects more than 20 million people in the United States.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercialization alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website:

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in Quarterly Report on Form 10-Q for the period ended June 30, 2005 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Bill Hodges, Chief Financial Officer
Fran Barsky, Director, Investor Relations


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.